Inventiva S.A.

Healthcare · Biotechnology · France

Last price 3.73 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 882.39M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-β, a pre-clinical program for the tr...